CJC-1295 with DAC

Thorner, M.O. et al. (2007). 'Growth hormone-releasing hormone (GHRH) analogs: therapeutic applications and clinical trials'. Growth Hormone & IGF Research, 17(5), 415-422. and Teichman, S.L. et al. (2006). 'Prolonged and stable elevation of IGF-I in man following a single subcutaneous injection of CJC-1295, a long-acting analogue of GHRH'. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

Administration before sleep is often discussed in research due to the natural pulsatile release of growth hormone during sleep. However, due to its long half-life, timing within the day may have less impact on overall GH pulsatility compared to shorter-acting GHRH mimetics.

• Ipamorelin (or other GHRPs like GHRP-2, GHRP-6)

  Commonly co-administered. CJC-1295 with DAC provides a stable GHRH signal, while GHRPs provide a potent, acute GH pulse. This combination leads to a more robust and physiological GH release, often resulting in greater increases in IGF-1 than either compound alone.

  Synergistic

• Somatostatin (endogenous)

  CJC-1295 with DAC works to counteract the inhibitory effects of somatostatin on GH release, thus enabling consistent GH secretion.

  Compatible

• Exogenous Growth Hormone (HGH)

  Combining CJC-1295 with DAC with exogenous HGH can lead to supra-physiological levels of GH and IGF-1, potentially increasing the risk of side effects such as acromegaly, insulin resistance, and carpal tunnel syndrome. Generally not recommended in research protocols.

  Use Caution

• Corticosteroids

  Corticosteroids can suppress GH secretion and reduce the effectiveness of GHRH analogs. Researchers should monitor outcomes closely if co-administered.

  Monitor Combination

• Insulin

  GH and IGF-1 can affect insulin sensitivity. Individuals with pre-existing insulin resistance or diabetes should monitor blood glucose carefully if conducting research with CJC-1295 with DAC.

  Monitor Combination

• Thyroid Hormones

  Thyroid hormones are essential for optimal GH function, and their adequate levels support the efficacy of GHRH analogs. No direct negative interaction is typically observed.

  Compatible

1. 1Gather materials: lyophilized peptide vial, bacteriostatic water (BAC water), sterile syringe (e.g., 1-3 mL), insulin syringe for administration, alcohol wipes.
2. 2Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol wipe.
3. 3Wipe the top of the BAC water vial with an alcohol wipe.
4. 4Using the larger syringe, draw the desired amount of BAC water (e.g., 1 mL per 2 mg of peptide for a 2mg/mL concentration) and slowly inject it into the peptide vial, aiming the water stream at the side of the vial, not directly onto the lyophilized powder.
5. 5Allow the peptide to dissolve naturally. Do not shake the vial. Gently swirl the vial or roll it between your hands for a few minutes if needed.
6. 6Once fully dissolved, the solution should be clear. Store the reconstituted peptide in the refrigerator (2-8°C).

Always use bacteriostatic water for reconstitution to ensure sterility and extend shelf life. Avoid shaking or vigorous agitation, as this can denature the peptide. Reconstitute slowly and gently.

• Weeks 1-4: Initial subtle improvements in sleep quality and recovery may be noticed. Increased vivid dreams are also commonly reported.
• Weeks 4-8: More noticeable improvements in body composition, such as a slight decrease in body fat and improved skin elasticity. Enhanced recovery from exercise.
• Weeks 8-12: Continued improvements in body composition, with potential for increased lean muscle mass and further reductions in body fat. Enhanced energy levels.
• Weeks 12-16: Peak effects typically observed, including significant improvements in body composition, overall well-being, and recovery. Users may experience better joint health and increased bone density (long-term).